Silence Therapeutics plc, (LON:SLN) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced today that that the company is scheduled to present at the following scientific conferences in March and April 2018.
Third Annual Oligonucleotide & Peptide Therapeutics (OPT)
March 26-28, 2018, Boston Marriott Cambridge, Cambridge, Boston, MA, US
Marie Lindholm, Head of Technology Innovation, will present on Tuesday March 27 at 1.20pm EDT. The presentation is entitled ‘Development of Novel Therapies Using Advanced GalNAc-siRNA Technology’.
Drug Discovery for Rare Diseases Symposium at OPT Congress
March 28, 2018, Boston Marriott Cambridge, Cambridge, Boston, MA, US
Torsten Hoffmann, COO, will present a case study on the company and its science entitled ‘Identification and Development of SLN124, a Conjugated GalNAc-siRNA Therapeutic for the Treatment of Iron Overload Disorders’ at 4.35pm EDT.
4th Annual Oligo 2018 Oxford
April 10, 2018, St Edmund Hall, Oxford, UK
Adrien Weingaertner, Group Leader, Drug Delivery, will make a presentation at 5.30pm BST. The presentation is entitled ‘Development of innovative hepatocyte-targeted siRNA conjugates for the treatment of liver-related disorders’.
9th Clinical Trials Innovation Programme
April, 26-27, 2018, Höchster Hof Hotel GmbH, Frankfurt, Germany
Manuela Aleku, Silence Therapeutics plc Head of Non-Clinical Development, will be presenting on Thursday April 26, 2018 at 9am CEST.
